Atlas Trials

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Clinical trial NCT04147351 · COMPLETED

Trial details

NCT number
NCT04147351
Sponsor
National Taiwan University Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC Stage IIIB~IV
Start date
2020-04-10
Primary completion
2026-02-04
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.